Mental Health Book

http://www.fpnotebook.com/

MirtazapineAka: Remeron, Norepinephrine Antagonist Serotonin Antagonist

Advertisement

  1. Indications: Major Depression
    1. Unresponsive to other Antidepressants
    2. Comorbid Anxiety Disorder
    3. Comorbid Insomnia
    4. Cachectic or chronically ill patients
  2. Mechanism
    1. Tetracyclic piperazinoazepine
    2. Norepinephrine Antagonist Serotonin Antagonist
      1. Blocks Pre-synaptic Alpha 2 Adrenergic Receptors
        1. Enhances central noradrenergic activity
      2. Blocks Post-synaptic 5-HT2, 5-HT3 Serotonin Receptors
        1. Enhances central Serotoninergic activity at 5-HT-1
    3. Significant Antihistamine activity
      1. Dose dependent effect
        1. Dose 15 mg: Antihistamine effects predominate
        2. Dose 45 mg: Noradrenergic effects predominate
      2. Antihistamine Symptoms
        1. Weight gain
        2. Sedation
  3. Pharmacokinetics
    1. Half-Life: 20 to 40 hours
  4. Dosing
    1. Start: 15 mg PO qhs
    2. Effective dose: 15 to 30 mg PO qhs
  5. Efficacy: Effective in treating Major Depression
    1. Superior to Placebo
    2. As effective as Elavil, Desyrel, and Prozac
  6. Adverse Effects
    1. Somnolence (54%)
      1. Consider dosing at bedtime to improve sleep
    2. Dry Mouth (25%)
    3. Increased appetite (17%)
    4. Weight gain (12%) may be significant
    5. Dizziness (7%)
  7. Precautions
    1. Agranulocytosis (occurs in 0.1% cases)
      1. Similar Incidence to other Antidepressants
      2. Does not warrant routine CBC monitoring
    2. Do not use within 14 days of MAO inhibitor
    3. Do not use with drugs causing excessive Sedation
      1. Alcohol
      2. Benzodiazepines
  8. Advantages
    1. No cardiac effects
    2. No or minimal Orthostatic Hypotension
    3. Low Incidence Antidepressant Induced Sexual Dysfunction
    4. No deaths have occurred in overdosage
  9. Drug Interactions
    1. Minimal Cytochrome P450 inhibition
  10. References
    1. Burrows (1997) Psychopharmacol 17:34S
    2. Hartmann (1999) Am Fam Physician 59(1):159
    3. Majeroni (1998) J Am Board Fam Pract 11:127

Mirtazapine (C0049506)

Definition (NCI)A synthetic derivative of piperazino-azepines, tetracyclic antidepressant Mirtazapine acts by an unknown mechanism that enhances central adrenergic and serotonergic transmission. Structurally unrelated to selective serotonin reuptake inhibitors, tricyclics, or monoamine oxidase inhibitors (MAOI), it also affects muscarinic transmission and has parasympatholytic properties. (NCI04)
ConceptsOrganic Chemical (T109) , Pharmacologic Substance (T121)
MSHC035133
English6-azamianserin, Mirtazapine, MIRTAZAPINE PREPARATION
Spanishmirtazapina
Parent ConceptsAntidepressive Agents (C0003289), Mianserin (C0025912), Mirtazapine (C0049506), [CN609] ANTIDEPRESSANTS, OTHER (C0973506), Tetracyclic antidepressant (C0360108), ANTIDEPRESSANTS,OTHER (C1579362)
SourcesLNC, MSH, MTH, MTHSPL, NCI, NDFRT, RXNORM, SCTSPA, SNOMEDCT, USPMG, VANDF
Derived from the NIH UMLS (Unified Medical Language System)


Remeron (C0525726)

ConceptsOrganic Chemical (T109) , Pharmacologic Substance (T121)
MSHC035133
EnglishCelltech brand of mirtazapine, Norset, Organon brand of mirtazapine, Remergil, Remeron, Zispin
SourcesMSH, NCI, RXNORM
Derived from the NIH UMLS (Unified Medical Language System)



Navigation Tree